62nd ASH Annual Meeting and Exposition: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

Oral and Poster Abstracts
Oral

AML, Biological, Adult, Animal models, Non-Biological, Diseases, Therapies, checkpoint inhibitors, Pediatric, chemotherapy, Biological Processes, Technology and Procedures, epigenetics, cytogenetics, Study Population, genomics, Clinically relevant, genetic profiling, Myeloid Malignancies, hematopoiesis, pharmacology, flow cytometry, immune mechanism, integrative -omics, NGS, microenvironment, RNA sequencing, molecular interactions, pathogenesis, pathways

Moderators:

and Ella R Thompson, PhD, BSc, University of Melbourne

Disclosures:

No relevant conflicts of interest to declare.

1:30 PM

688

Variation in Stem Cell Driven Hierarchies Underlies Clinical Outcome and Drug Response in AML

Andy G.X. Zeng, BSc^1,2, Amanda Mitchell, PhD¹^*, Oleksandr Galkin, PhD¹^*, Jean C.Y. Wang, MD, PhD^1,3, James A. Kennedy, MD PhD^1,4 and John E. Dick, PhD, FRS^2,5

¹Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
²Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
³Department of Medicine, University of Toronto, Toronto, ON, Canada
⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁵Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada

1:45 PM

689

Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Benjamin J. Huang, MD^1,2^*, Jenny L. Smith, MSc, MEd³^*, Rhonda E. Ries, MA³^*, Amanda R. Leonti, MS⁴^*, Erin Lynn Crowgey, PhD⁵^*, Scott N. Furlan, MD⁶^*, Timothy Shaw, PhD⁷^*, Lisa Wei, BS⁸, Yi-Cheng Wang, MS⁹^*, Robert B. Gerbing, MA⁹^*, Todd A. Alonzo, PhD^9,10^*, Todd M. Cooper, DO¹¹, Edward A. Kolb, MD¹², Xiaotu Ma, PhD¹³^*, Jason E Farrar, MD¹⁴, Timothy Junius Triche Jr., PhD¹⁵ and Soheil Meshinchi, MD, PhD^16,17

¹Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
²Department of Pediatrics, University of California, San Francisco, San Francisco, CA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Mountlake Terrace, WA
⁵Alfred I. duPont Hospital for Children, Wilmington, DE
⁶Fred Hutchinson Cancer Research Center, Seattle, WA
⁷Computational Biology, St. Jude Children's Hospital, Memphis, TN
⁸Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada
⁹Children's Oncology Group, Monrovia, CA
¹⁰Department of Preventive Medicine, University of Southern California, Monrovia, CA
¹¹Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
¹²Division of Oncology, Nemours Alfed I. duPont Hospital For Children, Wilmington, DE
¹³Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
¹⁴University of Arkansas For Medical Sciences, Little Rock, AR
¹⁵Van Andel Research Institute, Grand Rapids, MI
¹⁶Department of Pediatrics, University of Washington, Seattle, WA
¹⁷Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA

2:00 PM

690

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Hussein A Abbas, MD, PhD¹, Dapeng Hao²^*, Katarzyna Tomczak, PhD³^*, Praveen Barrodia²^*, Jin S. Im⁴, Patrick K Reville, MD⁵, Zoe Alaniz⁶^*, Wei Wang, MD, PhD⁷^*, Ruiping Wang, PhD⁸^*, Feng Wang, PhD⁸^*, Koichi Takahashi, MD, PhD⁸, Jing Ning, PhD⁹^*, Maomao Ding¹⁰^*, Jairo A. Matthews¹¹^*, Latasha Little, BS¹²^*, Jianhua Zhang, PhD²^*, Sreyashi Basu, PhD¹³^*, Courtney D. DiNardo, MD, MSc¹⁴, Tapan M. Kadia, MD¹⁵, Farhad Ravandi, MBBS¹⁶, Gautam Borthakur, MD¹⁷, Marina Konopleva, MD, PhD¹⁸, Guillermo Garcia-Manero, MD¹⁷, Michael R Green, PhD¹⁹, Gheath Alatrash²⁰, Padmanee Sharma²¹^*, James P Allison, PhD¹³^*, Steven M. Kornblau, MD²², Kunal Rai²^*, Linghua Wang, PhD⁸^*, P Andrew Futreal, PhD²^* and Naval Daver, MD²³

¹Division of Cancer Medicine, Medical Oncology Fellowship, UT M. D. Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, UT M. D. Anderson Cancer Center, Houston, TX
³Department of Translational Molecular Pathology, UT M. D. Anderson Cancer Center, Houston, TX
⁴Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Hematopathology, UT M. D. Anderson Cancer Center, Houston, TX
⁸Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Department of Biostatistics, UT M. D. Anderson Cancer Center, Houston, TX
¹¹Department of Leukemia, UT M. D. Anderson Cancer Center, Houston, TX
¹²Department of Genomics Medicine, UT M. D. Anderson Cancer Center, Houston, TX
¹³Department of Immunology, UT M. D. Anderson Cancer Center, Houston, TX
¹⁴Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
¹⁵Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
¹⁶Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁸Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
¹⁹Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
²⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²¹Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²²Department of Stem Cell Transplantation, M.D. Anderson Cancer Center University of Texas, Houston, TX
²³Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

2:15 PM

691

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD-Mutant AMLs

Suruchi Pacharne¹^*, Oliver M. Dovey, PhD²^*, Jonathan L Cooper³^*, Muxin Gu³^*, Vijay Baskar, PhD⁴^*, Mathias J Friedrich⁵^*, Malgorzata Gozdecka, PhD⁶^*, Sandeep S Rajan, PhD⁷^*, Etienne De Braekeleer, PhD, MSc⁴^*, Maxim Barenboim⁸^*, Grace Collord⁹^*, Hannes Postingl, PhD⁹^*, Ruben Bautista⁹^*, Milena Mazan, PhD¹⁰^*, Roland Rad, Prof., MD¹¹^*, Konstantinos Tzelepis³^*, Penny Wright¹²^* and George S. Vassiliou, MD, PhD, FRCPath, MRCP¹³^*

¹WELLCOME TRUST SANGER INSTITUTE, Cambridgeshire, United Kingdom
²Wellcome Trust Sanger Institute, Cambridge, United Kingdom
³Wellcome Sanger Institute, Cambridge, United Kingdom
⁴Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
⁵Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
⁶Haematological Cancer Genetics, Wellcome Sanger Institute, Cambridge, ENG, United Kingdom
⁷UK Dementia Research Institute at the University of Cambridge, Cambridge, United Kingdom
⁸, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
⁹Wellcom Sanger Institute, Cambridge, United Kingdom
¹⁰Selvita S.A., Krakow, Poland
¹¹Institute of Molecular Oncology and Functional Genomics, Technical University of Munich, Munich, Germany
¹²Cambridge University Hospitals NHS Trust, Cambridge, GBR
¹³Wellcome Trust Sanger Institute, Cambridge, ENG, United Kingdom

2:30 PM

692

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD¹, Farhad Ravandi, MBBS², Andrew H Wei, MBBS, PhD^3,4, Hervé Dombret, MD^5,6, Hartmut Döhner⁷, Felicitas Thol⁸, Maria Teresa Voso, MD⁹, Andre C. Schuh¹⁰, Kimmo Porkka^11,12, Ignazia La Torre¹³^*, Barry Skikne, MD^14,15^*, Keshava Kumar, PhD¹⁵^*, Qian Dong, DrPH¹⁵^*, C.L. Beach, PharmD¹⁵^*, Alberto Risueño¹⁶^*, Daniel Lopes de Menezes, PhD¹⁵^* and Gert Ossenkoppele, MD, PhD¹⁷^*

¹Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³The Alfred Hospital, Melbourne, Australia
⁴Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
⁵Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris, France
⁶Institut de Recherche Saint Louis, Université de Paris, Paris, France
⁷Ulm University Hospital, Ulm, Germany
⁸Medizinische Hochschule Hannover, Hannover, Germany
⁹University of Rome Tor Vergata, Rome, Italy
¹⁰Princess Margaret Cancer Centre, Toronto, ON, Canada
¹¹iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
¹²Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
¹³Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹⁴Kansas University Medical Center, Kansas City, KS
¹⁵Bristol Myers Squibb, Princeton, NJ
¹⁶BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol Myers Squibb Company, Seville, Spain
¹⁷Amsterdam UMC, Location VU University Medical Center, Amsterdam, Netherlands

2:45 PM

693

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

Kunhwa Kim, MD MPH¹^*, Abhishek Maiti, MBBS², Tapan M. Kadia, MD¹, Farhad Ravandi, MBBS¹, Naval Daver, MD¹, Naveen Pemmaraju, MD³, Gautam Borthakur, MD², Prithviraj Bose, MD¹, Ghayas C. Issa, MD², Nicholas J. Short, MD¹, Musa Yilmaz, MD², Yesid Alvarado, MD⁴, Alessandra Ferrajoli, MD¹, Elias Jabbour, MD², Nitin Jain, MD², Maro Ohanian, DO²^*, Koichi Takahashi, MD, PhD¹, Philip A. Thompson, MB, MS⁵, Caitlin R. Rausch, PharmD⁶^*, Kathryn Montalbano²^*, Sherry A. Pierce, BSN, BA¹^*, Keyur P. Patel, MBBS, PhD⁷, Guillermo Garcia-Manero, MD¹, Hagop M. Kantarjian, MD², Courtney D. DiNardo, MD, MSc¹ and Marina Konopleva, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
³University of Texas, MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁶Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

617A.O2.6 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches